A prospective,randomized,single-blind,comparative study of Inslow,palatinose-based liquid formula and Meibalance,standard balanced liquid formula,using viscera fat accumulation as a primary endpoint in adults patients with confirmed diagnosis of obesity and impaired glucose tolerance.

A prospective,randomized,single-blind,comparative study of Inslow,palatinose-based liquid formula and Meibalance,standard balanced liquid formula,using viscera fat accumulation as a primary endpoint in adults patients with confirmed diagnosis of obesity and impaired glucose tolerance. - A prospective,randomized,single-blind,comparative study of Inslow,palatinose-based liquid formula and Meibalance,standard balanced liquid formula ingested for a certain period,using visceral fat accumulation as a primary endpoint in adults patients with obesity and impaired glucose tolerance.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001301

Enrollment

Registered

2009-01-01

Start date

2008-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity and impaired glucose tolerance

Interventions

Inslow(palatinose-based liquid formula) ingested group 1.Period of intervention: a)nutritional consultation period

3 months b)period of ingestion

6 months 2.Intake amount per day:200 Kcal 3.Intake frequency per day:once a day Meibalance(standard balanced liquid formula) ingested group 1.Period of intervention: a)nutritional consultation p

6 months 2.Intake amount per day:200 Kcal 3.Intake frequency per day:once a day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Inclusion criteria at the preliminary registration 1.BMI>=25Kg/m2 2.Fasting glucose concentrations: 100-125mg/dL 3.HbA1c 5.2%-6.5% 4.Volunteers with written informed consent 2)Inclusion criteria at the registration 1.BMI>=25kg/m2 2.Fasting glucose concentrations: 100-125mg/dL 3.HbA1c 5.2%-6.5% 4.Successful volunteers in the nutritional period

Exclusion criteria

Exclusion criteria: 1.Participants recieveing anti-diabetic drug 2.Deep chronic drinker 3.Participants with following complications or with past histry *Exocrine diseases of pancreas: Pancreatitis;Tumor; Hemochromatosis,etc. *Endocrine diseases: Cushings's syndrome;Acromegaly, Pheochromocytoma; Hyperthyroidism,etc. *Hepatic diseases:Chronic hepatitis, Hepatic cirrhosis *Patients with gastrectmy or with chronic gastro-enteral disease 4.Female who is pregnant, in a lactation period, child-bearing potential or wishing to be pregnant. 5.Participants judged to be inadequate by the investigator.

Design outcomes

Primary

Measure	Time frame
Visceral fat accumulation	—

Secondary

Measure	Time frame
Hemoglobin A1c HOMA index Area under the curb of glucose concentration after 75gOGTT Area under the curb of insurin concentration after 75gOGTT	—

Countries

Japan

Contacts

Public ContactHiromitsu Aonuma

Meiji Dairies Corporation Food Science Institute Nutrition Research Department Clinical Study and Scientific Assessment Section

HIROMITSU_AONUMA@MEIJI-MILK.COM0465-37-3617

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026